MAYNE PHARMA (IRELAND) LIMITED

Overview

MAYNE PHARMA (IRELAND) LIMITED is a pharmaceutical company registered in Ireland with CRO number 671407. The company is involved in therapeutics and healthcare, with a focus on women’s health and dermatology. Public reports indicate it holds patents for products such as Nextstellis®, Annovera®, Bijuva®, Imvexxy®, and Vyleesi®, and has FDA-approved manufacturing sites in the U.S. and Australia. A $430 million acquisition deal was proposed in early 2025 by Cosette Pharmaceuticals, aiming to expand its specialty portfolio and global reach. However, the deal was terminated in June 2025 due to concerns over Mayne’s financial performance and a warning from the FDA regarding promotional claims for its contraceptive product, Nextstellis. Mayne has stated it intends to contest the termination, asserting no material adverse change. The company operates in the pharmaceutical sector, with business activities centered on drug development and manufacturing. Beyond registry-level identification, no further business details are publicly captured.

Location & registered address

70 Sir John Rogerson'S Quay

D02 R296 Ireland

Dublin 2

Dublin 2

Dublin

Ireland

Industry classification

NACE Rev. 2 — 82.99

Class 82.99 covers other business support service activities not elsewhere classified.

→ All NACE 82.99 companies in Ireland · In Dublin